Abstracts tagged "Biologicals"

Abstract Number: 0995 • ACR Convergence 2024
What Is the Carbon Footprint of Adalimumab Originator and Its Various Biosimilar Drugs?
Ines Moninot¹, ROLAND CHAPURLAT², Elodie FEURER¹, Pierre-Jean Cottinet³, Minh-Quyen Le³ and Aurélie Fontana¹, ¹Hospices Civils Lyon, Lyon, France, ²INSERM 1033, LYON, France, ³INSA Lyon, Lyon, France
Background/Purpose: In developed countries, the impact of healthcare systems on the environment is sizeable (roughly 8% of the carbon footprint). So, it is essential to…
Abstract Number: 1378 • ACR Convergence 2024
Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis
Marta Hernández-Díaz¹, Iván Ferraz-Amaro², Sergio Santos-Concepción³, Javier Castro³, Vanesa Hernandez⁴, Beatriz Tejera Segura⁵, Cristina Luna⁶, Esmeralda Delgado-Frías² and Federico Diaz-González², ¹Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ²Hospital Universitario de Canarias, La Laguna, Spain, ³Universidad de La Laguna, La Laguna, Spain, ⁴Rheumatology department. Hospital Universitario de Canarias, La Laguna, Spain, ⁵Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ⁶Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz, Spain
Background/Purpose: Tocilizumab (TCZ) is used in diseases characterized by markedly elevated inflammatory markers and elevated pro-inflammatory cytokines like rheumatoid arthritis (RA), juvenile idiopathic arthritis and…
Abstract Number: 1474 • ACR Convergence 2024
Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Christopher Ritchlin¹, Ennio Lubrano², Maria Sole Chimenti³, Evan Leibowitz⁴, Mohamed Sharaf⁵, Oyediran Adelakun⁶, Emmanouil Rampakakis⁷, Francois Nantel⁸, Frederic Lavie⁹ and Atul Deodhar¹⁰, ¹Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ²Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy, ³Rheumatology, Allergology and Clinical Immunology, System Medicine Department, University of Rome Tor Vergata, Rome, Italy, ⁴Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, ⁶Janssen Research & Development, LLC, Titusville, NJ, ⁷McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁸Nantel Medsci Consult, Montreal, QC, Canada, ⁹Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ¹⁰Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: In previous DISCOVER (D)1 and 2 analyses, the fully human IL-23p19-subunit inhibitor guselkumab (GUS) was associated with robust and sustained improvement in PsA signs/symptoms…
Abstract Number: 1756 • ACR Convergence 2024
What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
Jette Heberg¹, Stylianos Georgiadis², Marion Pons³, Anne Gitte Loft⁴, Brigitte Michelsen⁵, Louise Linde³, Daniela DiGuiseppe⁶, Simon Horskjær Rasmussen³, Mehrdad Kazemi³, Gary Macfarlane⁷, Gareth Jones⁷, Karin Laas⁸, Sigrid Vorobjov⁹, Isabel Castrejon¹⁰, Ziga Rotar¹¹, Katja Perdan-Pikmajer¹¹, Ladislav Šenolt¹², Jana Baranová¹³, Bente Glintborg¹⁴, Adrian Ciurea¹⁵, Miguel Bernardes¹⁶, Paula Valente¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Gunnstein Bakland¹⁹, Catalin Codreanu²⁰, Corina Mogosan²⁰, Florenzo Iannone²¹, Roberto Caporali²², Johan Karlsson Wallman²³, Vappu Rantalaiho²⁴, Ritva Peltomaa²⁵, Karel Pavelka²⁶, Pavel Horak²⁷, Diogo Esperança Almeida²⁸, Sara Dias Rodrigues²⁹, Lykke Oernbjerg², Mikkel Ostergaard³⁰ and Merete Hetland³¹, ¹Rigshospitalet Glostrup, København V, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Rigshospitalet Glostrup, Glostrup, Denmark, ⁴Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, ⁷University of Aberdeen, Aberdeen, United Kingdom, ⁸East-Tallinn Central Hospital, Tallinn, Estonia, ⁹National Institute for Health Development, Tallinn, Estonia, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁵University Hospital Zurich, Zürich, Switzerland, ¹⁶São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁷Rheumatology Department, Hospital de São Sebastião, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, University Hospital North Norway, Tromsø, Norway, ²⁰University of Medicine and Pharmacy, Bucharest, Romania, ²¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²³Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²⁴Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ²⁵Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ²⁶Institute of Rheumatology and Charles University, Praha, Czech Republic, ²⁷3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ²⁸Hospital de Braga, Braga, Portugal, ²⁹Serviço de Reumatologia, Hospital Egas Moniz, Unidade Local de Saúde Lisboa Ocidental, Lisboa, Portugal, ³⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) and Interleukin-17Ai inhibitors (IL-17Ai) have shown effectiveness in achieving low disease activity (LDA) in patients with axial spondyloarthritis (axSpA).…
Abstract Number: 2046 • ACR Convergence 2024
Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents
Antonio Brucato¹, Elisa Ceriani², Francesco Agozzino³, Silvia Berra⁴, Antonio Gidaro², Silvia Macchi⁵, Letizia Vena⁵, Paolo Bindi⁵, Alberto Pavarani⁶, Francesco Moda⁷, Ludovico Luca Sicignano⁸, Celeste Murace⁸, Elena Verrecchia⁸, Caterina Chiara Decarlini⁹, Silvia Maestroni¹⁰, Gabriella Marinaro⁴, Lucia Trotta³, Massimo Pancrazi³, Lisa Serati³, Enrica Negro³, Claudia Gabiati³, Elisa Calabrò³, Angela Mauro¹¹, Luisa Carrozzo³, Emanuele Bizzi³ and Massimo Imazio¹², ¹Department of Biomedical and Clinical Sciences, University of Milano, Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milano, Lombardia, Italy, ²Department of Internal Medicine, Ospedale Luigi Sacco, Milano, Milan, Italy, ³Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milan, Italy, ⁴Department of Internal Medicine, Ospedale Fatebeneratelli, Milano, Milano, Italy, ⁵University of Milano, Milan, Italy, ⁶University of Milano, Milan, ⁷Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁸Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Rome, Italy, ⁹Cardiology Division, Cardiovascular Department, San L. Mandic Hospital, Merate, Lecco, Italy, ¹⁰Internal Medicine Department, Papa Giovanni XXIII Hospital, Bergamo, Bergamo, Italy, ¹¹Pediatric Rheumatology Unit, Department of Childhood and Developmental Medicine, Fatebenefratelli-Sacco Hospital, Milan, Italy, ¹²University of Udine, and Cardiothoracic Department, University Hospital Santa Maria della Misericordia, Udine, Milan, Italy
Background/Purpose: Recurrent pericarditis (RP) challenges pts and clinicians in terms of long-term management. Objective of this study was to evaluate the remission rate (drug-free for…
Abstract Number: 2354 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
Alan Kivitz¹, Liliana Sedova², Melvin Churchill³, Cynthia Vizcaya⁴, Reema Sutariya⁵, Wenhao Cao⁵ and Atul Singhal⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institute of Rheumatology, Prague, and Clinic of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Southwest Arthritis Research Group, Mesquite, TX
Background/Purpose: To assess baseline demographics and clinical characteristics of patients with PsA that are most associated with achievement of clinical response to intravenous (IV) secukinumab…
Abstract Number: 2582 • ACR Convergence 2024
Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Iain McInnes¹, Laura Coates², Philip Mease³, Alexis Ogdie⁴, Arthur Kavanaugh⁵, Lihi Eder⁶, Georg Schett⁷, Alan Kivitz⁸, Nuala Brennan⁹, Alex Godwood⁹, Eva Cullen⁹, Kristian Reich⁹, Christopher Ritchlin¹⁰ and Joseph F. Merola¹¹, ¹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ²University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵University of California San Diego, La Jolla, CA, ⁶University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁰Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹¹UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sonelokimab is a novel humanized Nanobody designed to inhibit IL-17A and IL-17F and penetrate clinically relevant sites of inflammation. The 24-week Phase 2 ARGO…
Abstract Number: 0231 • ACR Convergence 2024
Imaging Characteristics and Demographic Variations in Patients with Axial Spondylarthritis, Axial Psoriatic Arthritis, and Inflammatory Bowel Disease-Related Arthritis with Axial Involvement: Insights from a Single Center at Cleveland Clinic Abu Dhabi
Rajaie Namas¹, Ahlam Almarzooqi², Sarah Al Qassimi³ and Esat Memisoglu³, ¹Cleveland Clinic Abu Dhabi, Detroit, MI, ²Emirates Health Services, Sharjah, United Arab Emirates, ³Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
Background/Purpose: Spondyloarthropathies (SpAs) are a group of seronegative, inflammatory arthritides, including axial spondylarthritis (ax-SpA), axial psoriatic arthritis (ax-PsA), and inflammatory bowel disease related arthritis with…
Abstract Number: 0447 • ACR Convergence 2024
Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer’s Global Safety Database
Connie Lin¹, Anja Geldhof², Mauricio Ballina³, Hetal Patel⁴ and Hewei Li⁵, ¹Janssen R&D US, Horsham, PA, ²Director Postmarketing Commitments, Leiden, Netherlands, ³Actelion Research & Development, Basel, Switzerland, Gewerbestrasse, Basel-Landschaft, Switzerland, ⁴Pharmaceutical Companies of Johnson & Johnson, Naperville, IL, ⁵Janssen Pharmaceutical, Hopewell Township, NJ
Background/Purpose: Data pertaining to the use of biologics in immunologic diseases are limited on their use during pregnancy. Guselkumab (GUS) is a human IgG1λ mAb…
Abstract Number: 0533 • ACR Convergence 2024
Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial
Maike Wientjes¹, Sadaf Atiqi², Gertjan Wolbink³, Michael Nurmohamed⁴, Maarten Boers⁵, Femke Hooijberg², Theo Rispens⁶, Annick De Vries⁶, Floris Loeff⁶, Ronald Van Vollenhoven⁷, Sofia Ramiro⁸, Noortje van Herwaarden⁹, Bart van den Bemt¹⁰ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Reade, Amsterdam, Netherlands, ³Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Reade and Amsterdam UMC, Kortenhoef, Netherlands, ⁵Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ⁶Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands, ⁹Sint Maartenskliniek, Nijmegen, Netherlands, ¹⁰Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands
Background/Purpose: Adalimumab is an effective and safe treatment for RA, however a substantial proportion of RA patients discontinue its use due to inefficacy. Upon failure,…
Abstract Number: 0671 • ACR Convergence 2024
Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Victoria Werth¹, Joseph F. Merola², Qianyun Li³, Weihong Yang³ and Catherine Barbey⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²UT Southwestern Medical Center, Dallas, TX, ³Biogen, Cambridge, MA, ⁴Biogen, Baar, Switzerland
Background/Purpose: In the randomized, placebo-controlled Phase 2 LILAC study of litifilimab (NCT02847598), Part B (participants with active CLE with/without SLE) met its primary endpoint of…
Abstract Number: 1005 • ACR Convergence 2024
Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
Nur Barlas, Sait Barlas, Stefan Milutinovic and Shristi Basnyat, Florida State University College of Medicine Internal Medicine Residency Program at Lee Health, Cape Coral
Background/Purpose: Janus Kinase (JAK) inhibitors are the agents of choice for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis when other DMARDs are…
Abstract Number: 1379 • ACR Convergence 2024
Association Between Body Mass Index and the Persistence of Non-TNF-Targeted Biologics in Patients with Rheumatoid Arthritis
Dong-Jin Park¹, Hyemin Jeong², Sung-Eun Choi³, Ji-Hyoun Kang² and Shin-Seok Lee⁴, ¹Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Chonnam National University Hospital, Gwangju, South Korea, ³Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Recent studies have shown the impact of obesity on achieving low disease activity (LDA) or remission in rheumatoid arthritis (RA) patients treated with TNF…
Abstract Number: 1482 • ACR Convergence 2024
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Atul Deodhar¹, Eva Dokoupilova², Cynthia Vizcaya³, Reema Sutariya⁴, Weibin Bao⁴, Karen Kapur³, Susanne Rohrer³ and Alan Kivitz⁵, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Medical Plus, s.r.o., Uherske Hradiste, and Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Prague, Czech Republic, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Altoona Center for Clinical Research, Duncansville, PA

Background/Purpose: This post hoc analysis of the INVIGORATE-1 study evaluated potential predictors of Ankylosing Spondylitis international Society (ASAS) 40 response in patients with axial spondyloarthritis…
Abstract Number: 1759 • ACR Convergence 2024
Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study
Denis Poddubnyy¹, Juergen Braun², Pedro M Machado³, Victoria Navarro Compán⁴, Lianne S Gensler⁵, Kay Geert Hermann⁶, Erhard Quebe-Fehling⁷, Christelle C Pieterse⁸, Aimee Readie⁹, Corine Gaillez⁷ and Xenofon Baraliakos¹⁰, ¹Charite-Universitatsmedizin Berlin, Berlin, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁴La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Charite Medical School, Berlin, Germany, ⁷Novartis Pharma AG, Basel, Switzerland, ⁸Syneos Health, Amsterdam, Netherlands, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Previous studies have identified predictors of radiographic spinal progression in patients with axial spondyloarthritis (axSpA). In this post hoc analysis of the SURPASS study…

« Previous Page
1
…
6
7
8
9
10
…
54
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].